DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+1.54%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$266M
AUM Growth
+$266M
(+15%)
Cap. Flow
+$27.1M
Cap. Flow
% of AUM
10.17%
Top 10 Holdings %
Top 10 Hldgs %
46.64%
Holding
94
New
15
Increased
27
Reduced
15
Closed
6
Top Buys
| 1 |
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
|
$3.74M |
| 2 |
Quince Therapeutics
QNCX
|
$2.78M |
| 3 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
$2.25M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
$2.18M |
| 5 |
Accuray
ARAY
|
$2.03M |
Top Sells
| 1 |
GNCA
Genocea Biosciences, Inc.
GNCA
|
$4.92M |
| 2 |
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
|
$1.59M |
| 3 |
ADXS
Advaxis, Inc.
ADXS
|
$1.2M |
| 4 |
Arbutus Biopharma
ABUS
|
$884K |
| 5 |
Savara
SVRA
|
$813K |
Sector Composition
| 1 | Healthcare | 91.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$261M
| $39.7M | 14.91% | 13,680,554 | – | – |
|
|
SAGE
2
DELISTED
Sage Therapeutics
SAGE
| $22.7M | 8.52% | 123,806 | – | – |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $11.6M | 4.37% | 123,218 +3,500 | +3% | +$330K |
|
4
AtriCure
ATRC
$1.84B
| $9.51M | 3.58% | 318,729 | – | – |
|
|
ALDR
5
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $7.49M | 2.81% | 636,013 +65,000 | +11% | +$765K |
|
6
Ascendis Pharma
ASND
$11.8B
| $6.84M | 2.57% | 59,380 +15,000 | +34% | +$1.73M |
|
7
Galapagos
GLPG
$2.07B
| $6.77M | 2.54% | 52,509 +2,900 | +6% | +$374K |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $6.73M | 2.53% | 140,764 +11,000 | +8% | +$526K |
|
9
iShares Biotechnology ETF
IBB
$5.6B
| $6.7M | 2.52% | 61,400 | – | – |
|
|
AERI
10
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $6.07M | 2.28% | 205,440 +53,670 | +35% | +$1.59M |
|
11
Wave Life Sciences
WVE
$1.53B
| $5.68M | 2.13% | 217,554 +27,000 | +14% | +$704K |
|
|
ARNA
12
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $5.51M | 2.07% | 93,942 | – | – |
|
|
ARQL
13
DELISTED
Arqule Inc
ARQL
| $5.48M | 2.06% | 497,762 +124,598 | +33% | +$1.37M |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $5.46M | 2.05% | 64,608 +9,600 | +17% | +$811K |
|
15
DexCom
DXCM
$29.5B
| $5.45M | 2.05% | 36,338 +4,000 | +12% | +$599K |
|
16
Cytokinetics
CYTK
$4.23B
| $5.37M | 2.02% | 477,196 +76,902 | +19% | +$865K |
|
17
argenx
ARGX
$43.6B
| $4.5M | 1.69% | 31,750 -3,900 | -11% | -$552K |
|
|
TVRD
18
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $4.41M | 1.66% | 205,011 +61,400 | +43% | +$1.32M |
|
|
BHVN
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.16M | 1.56% | 95,000 +15,000 | +19% | +$657K |
|
20
Akebia Therapeutics
AKBA
$833M
| $4.02M | 1.51% | 830,538 +115,000 | +16% | +$557K |
|
|
LMNX
21
DELISTED
Luminex Corp
LMNX
| $4.01M | 1.51% | 194,091 +55,700 | +40% | +$1.15M |
|
|
ELOX
22
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| $3.74M | 1.41% | +375,000 | New | +$3.74M |
|
23
VYNE Therapeutics
VYNE
$8.16M
| $3.59M | 1.35% | 600,030 | – | – |
|
24
Xenon Pharmaceuticals
XENE
$2.98B
| $3.26M | 1.23% | 330,667 | – | – |
|
|
BLUE
25
DELISTED
bluebird bio
BLUE
| $3.24M | 1.22% | 25,500 -1,500 | -6% | -$191K |
|